Secondly, in a prophylactic context, the iPSC vaccine could be utilized to treat individuals at high risk of developing cancer, such as those with Lynch syndrome, IBD, Li-Fraumeni syndrome, chronic hepatitis B infection, hereditary chronic pancreatitis, or pathogenic germline mutations in BRCA1/2 genes 38-42. This evidence concerns the gene BRCA1 and Li-Fraumeni syndrome.